



AOXIN Q & M DENTAL GROUP LIMITED
(Company Registration Number: 201110784M)
(Incorporated in the Republic of Singapore)

**ACUMEN DIAGNOSTICS PTE. LTD. APPOINTS UOB KAY HIAN PRIVATE LIMITED AS
ARRANGER TO EXPLORE NASDAQ LISTING**

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR ANY SECURITIES NOR IS IT CALCULATED TO INVITE ANY SUCH OFFER OR INVITATION. IN PARTICULAR, THIS ANNOUNCEMENT DOES NOT CONSTITUTE AND IS NOT AN OFFER TO SELL OR AN INVITATION OR A SOLICITATION OF ANY OFFER TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN THE UNITED STATES OF AMERICA (THE "USA") OR ELSEWHERE. SECURITIES MAY NOT BE OFFERED OR SOLD IN THE USA ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION UNDER APPLICABLE USA LAWS AND REGULATIONS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE USA WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM ACUMEN DIAGNOSTICS PTE. LTD. ("ADPL") AND WILL CONTAIN DETAILED INFORMATION ABOUT ADPL, ITS MANAGEMENT AND ITS FINANCIAL STATEMENTS.

THIS ANNOUNCEMENT IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE USA OR TO PERSONS IN THE USA OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

1. INTRODUCTION

- 1.1 The Board of Directors (the "**Board**" or the "**Directors**") of Aoxin Q & M Dental Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") wishes to announce that its 49% associated company, Acumen Diagnostics Pte. Ltd. ("**ADPL**") is exploring a proposed listing of its securities on the NASDAQ stock exchange in New York, USA (the "**Proposed NASDAQ Listing**").
- 1.2 In this regard, ADPL has appointed UOB Kay Hian Private Limited ("**UOBKH**") to assist ADPL with the listing evaluation and all relevant preparatory work including the selection of professional advisers and underwriting banks in relation to the Proposed NASDAQ Listing and fund raising exercise.

2. RATIONALE

NASDAQ is one of the most well-known and prestigious listing platforms in the world. It is known for technology and innovation, and it is home to digital, biotechnology, and other

cutting edge companies. The board of directors of ADPL believes that having a listing status in a leading global capital market of the status of NASDAQ is beneficial to ADPL as this provides ADPL with ready access to the world's largest economy, an expanded investor base and additional sources of financing. The Proposed NASDAQ Listing is also an excellent opportunity for ADPL to enhance its corporate profile as it seeks to further expand its business.

3. FURTHER UPDATE

As at the date of this announcement, given ADPL is still at the preparatory and evaluation stage in relation to the Proposed NASDAQ Listing, no application has been made to the NASDAQ or to any other regulatory authority or stock exchange.

Subject to any applicable regulatory requirements, the Company will keep its shareholders ("**Shareholders**") updated on the progress of the Proposed NASDAQ Listing.

4. CAUTION

Whilst the Proposed NASDAQ Listing promises to be an exciting new milestone for ADPL and the Group, Shareholders should note that there is no certainty or assurance that it will materialise. Amongst others, the Proposed NASDAQ Listing is subject to the results of the preparatory work being undertaken, prevailing market conditions and circumstances surrounding ADPL, and the Group, the approval of the relevant regulatory authorities and if required, the approval of Shareholders and shareholders of Q&M Dental Group (Singapore) Limited (ADPL's 51% shareholder) at their respective general meeting to be convened.

Further, the board of directors of ADPL may, notwithstanding that all requisite regulatory approvals and shareholders' approval have been obtained, decide not to proceed with the Proposed NASDAQ Listing, if after assessing various factors including the prevailing general economic and capital market conditions, the board of directors of ADPL deems that it is not in the best interests of ADPL to proceed with the same.

Shareholders and other investors are advised to exercise caution when trading in the securities of the Company, and to refrain from taking any action which may be prejudicial to their interests. In the event that Shareholders and other investors are in any doubt, they should consult their stockbrokers, bank managers, solicitors, accountants, tax advisers or other professional advisers.

By Order of the Board

Aoxin Q & M Dental Group Limited

Dr. Shao Yongxin
Executive Director and Group Chief Executive Officer
17 January 2022

For more information, please contact:

Deputy CEO

Ryan San Yi Leong @ Tan Yi Leong

Tel: 6235 1188

Email: ryan@aoxin.sg

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg